CompletedPhase 2NCT02015481
Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients
Studying Oculopharyngeal muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bioblast Pharma Ltd.
- Principal Investigator
- Yoseph Caraco, M.DHadassah Medical Organization
- Intervention
- Cabaletta(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2014 – 2016
Study locations (4)
- UCLA, Los Angeles, California, United States
- Tahseen Mozaffar, Orange, California, United States
- Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
- Hadassah medical center, Jerusalem, Israel
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02015481 on ClinicalTrials.govOther trials for Oculopharyngeal muscular dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06185673A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With DysphagiaBenitec Biopharma, Inc.
- RECRUITINGNCT07118280Oral Health, Saliva Viscosity and Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)Sheba Medical Center
- RECRUITINGNCT07146256Natural History of Oculo-Pharyngeal Muscular Dystrophy (OPMD) - Israel National OPMD RegistrySheba Medical Center